

**Hybrid Conference Programme**

Start (BST)	Finish (BST)	Presenter details
<b>Monday 11 May 2026</b>		
11:30	12:30	<b>Registration, lunch and networking</b>
12:15		<i>Briefing for Keynote speaker and session 1 speakers, microphone runners, chair, moderator &amp; committee - Auditorium</i>
12:30	12:45	<b>Welcome and introductions</b>
		<b>Wellcome Connecting Science:</b> <i>Michelle Bishop, Wellcome Connecting Science, UK</i>
		<b>Scientific programme committee:</b> <a href="#">Christine Stabell Benn, University of Southern Denmark, Denmark</a> <a href="#">Eleanor Fish, University of Toronto, Canada</a> <a href="#">Katie Flanagan, RMIT University, University of Tasmania &amp; Australian Technical Advisory Group on Immunization, Australia</a> <a href="#">Jim Buttery, University of Melbourne, Australia</a> <a href="#">Sabra Klein, Johns Hopkins, USA</a>
12:45	13:30	<b>Keynote lecture 1</b>
12:45	13:15	The Inflection Point: Vaccinology at the Crossroads of Biology, Technology, and Public Health <a href="#">Gregory Poland, Mayo Clinic, USA</a>
13:15	13:30	Discussion
13:30	14:30	<b>Session 1: The importance of genomics for immunomodulatory effects of vaccines</b>
13:30	14:00	From Systems Vaccinology to Universal Vaccines - virtual presentation <a href="#">Bali Pulendran, Stanford University, USA</a>
14:00	14:30	A systems immunology approach to uncover how the gut microbiota supports optimal infant vaccine responses <a href="#">David Lynn, Flinders University, Australia</a>
14:30	15:00	Coffee break
14:45		<i>Briefing for Session 2 speakers, chair, moderator &amp; committee - Auditorium</i>
15:00	16:30	<b>Session 2: Immunobiology of vaccines over the life course</b>
15:00	15:30	How estrogens and menopause impact immunity to influenza vaccines <a href="#">Sabra Klein, Johns Hopkins, USA</a>
15:30	16:00	Trained immunity: from basic mechanisms to vaccination <a href="#">Mihael Netea, Radboud University, The Netherlands</a>
16:00	16:30	Adjuvanted and high dose influenza vaccines trigger distinct molecular pathways in older adults <a href="#">Katie Flanagan, RMIT University, University of Tasmania &amp; Australian Technical Advisory Group on Immunization, Australia</a>
16:30	16:40	Comfort break
16:40	17:40	<b>Session 2: Immunobiology of vaccines over the life course continued</b>
16:40	16:55	Differential humoral, cellular, and inflammatory responses to an adjuvanted herpes zoster vaccine and an inactivated influenza vaccine in young and older adults <a href="#">Gizem Kiliç, Radboud University Medical Center, Netherlands</a>
16:55	17:10	Investigating the Mechanisms of Action of Vaccine Adjuvant AS01 in Human Lymph Nodes <a href="#">Anthony Cunningham, Centre for Virus Research, The Westmead Institute for Medical Research, Australia</a>
17:10	17:50	Panel Discussion <a href="#">Gregory Poland, Mayo Clinic, USA</a> <a href="#">Bali Pulendran, Stanford University, USA</a> <a href="#">David Lynn, Flinders University, Australia</a> <a href="#">Sabra Klein, Johns Hopkins, USA</a> <a href="#">Mihael Netea, Radboud University, The Netherlands</a> <a href="#">Katie Flanagan, RMIT University, University of Tasmania &amp; Australian Technical Advisory Group on Immunization, Australia</a>
17:50	18:30	<b>Poster pitch talks for poster session 1</b>
18:30	19:30	<b>Poster session 1</b>
19:30	21:00	Dinner
19:30		Bar open (card payments only)

**Tuesday 12 May 2026**

08:15		Briefing for Keynote 2 Session 3 speakers, chair & moderator - Auditorium
<b>09:00</b>	<b>09:30</b>	<b>Keynote lecture 2</b>
09:00	09:30	Gold Standard Sickness: American Immunization <a href="#">Angela Rasmussen, University of Saskatchewan, Canada</a>
<b>09:30</b>	<b>10:30</b>	<b>Session 3: Vaccine Benefit-Risk</b>
09:30	10:00	Harnessing adversomics for vaccine safety evaluation <a href="#">Karina Top, University of Alberta, Canada</a>
10:00	10:30	Real world datasets informing vaccine safety <a href="#">Jim Buttery, University of Melbourne, Australia</a>
10:30	11:00	Coffee break
<b>11:00</b>	<b>13:00</b>	<b>Session 3: Session 3: Vaccine Benefit-Risk continued</b>
11:00	11:30	Supporting the RSV older adult's vaccine programme through robust epidemiological vaccine safety investigations: Guillian Barré syndrome <a href="#">Julia Stowe, UK Health Security Agency, UK</a>
11:30	11:45	Vaccine pharmacovigilance and sex - immune vs reporting reality? <a href="#">Hazel Clothier, Centre for Health Analytics, Melbourne Children's Campus, Australia</a>
11:45	12:00	Population-Level Impact and Genotype Trends of Rotavirus After National Introduction of Rotavac and Rotasiil in India (2016–2023) <a href="#">Tintu Varghese, Christian Medical College, India</a>
12:00	13:00	Panel <a href="#">Angela Rasmussen, University of Saskatchewan, Canada</a> <a href="#">Karina Top, University of Alberta, Canada</a> <a href="#">Jim Buttery, University of Melbourne, Australia</a> <a href="#">Julia Stowe, UK Health Security Agency, UK</a> <a href="#">Ofar Levy, Harvard Medical School, USA</a> <a href="#">Hans-Henrik Kristensen, AJ Vaccines, Denmark</a> <a href="#">Eleanor Fish, University of Toronto, Canada</a>
13:00	14:00	Lunch and networking
13:45		Briefing for workshop Session 4 speakers, chair & moderator - Auditorium
<b>14:00</b>	<b>15:00</b>	<b>WORKSHOP: How to talk about vaccines and how to involve young researchers in studying vaccines, in the era of vaccine scepticism</b>
14:00	15:00	How to talk about vaccines and how to involve young researchers in studying vaccines, in the era of vaccine scepticism <a href="#">Caitlín Jarrett, London School of Hygiene &amp; Tropical Medicine, UK</a> <a href="#">Marco De Ambrogi, The Lancet Group, UK</a>
<b>15:00</b>	<b>16:00</b>	<b>Session 4: Immunomodulatory effects of vaccines on health and disease</b>
15:00	15:30	Randomized Clinical Trials with BCG: CNS and Glycolysis Benefits with Clinical Endpoints <a href="#">Denise Faustman, Harvard University, USA</a>
15:30	16:00	Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts <a href="#">Pascal Geldsetzer, Stanford University, USA</a>
16:00	16:30	Coffee break
<b>16:30</b>	<b>18:00</b>	<b>Session 4: Session 4: Immunomodulatory effects of vaccines on health and disease continued</b>
16:30	17:00	Harnessing the power of trained immunity in asthma <a href="#">Eva Kaufmann, McGill University, Canada</a>
17:00	17:30	mRNA vaccines as universal innate immune stimulants as anti-cancer therapy <a href="#">Steven Lin, University of Texas MD Anderson Cancer Center, USA</a>
17:30	17:45	Beneficial non-specific effects of nanoparticles: lung allergic inflammation and cancer <a href="#">Magdalena Plebanski, RMIT University, Australia</a>
17:45	18:00	A bacterial-fungal-viral co-infection may be a proximate cause of Alzheimer's and Parkinson's—offering more explanation for the BCG vaccine's protective efficacy <a href="#">Annefse Barron, Department of Bioengineering, Schools of Medicine and of Engineering, Stanford University, United States</a>
18:00	18:15	Innate immune training effects of a neonatal live-attenuated oral Rotavirus (RV3-BB) vaccination <a href="#">Prisca Benedicto-Matambo, Kamuzu University of Health Sciences, Medical Laboratory Sciences Department, Malawi</a>
18:15	18:30	Discussion
<b>18:30</b>	<b>19:00</b>	<b>Poster pitch talks</b>
<b>19:00</b>	<b>20:00</b>	<b>Poster session</b>
<b>20:00</b>	<b>21:00</b>	<b>Dinner</b>
20:00		Bar open (card payments only)

Wednesday 13 May 2026		
08:15		Briefing for Session 5 speakers, chair & moderator - Auditorium
<b>08:30</b>	<b>10:30</b>	<b>Session 5: Vaccine immunomodulatory effects informing vaccine policies</b>
08:30	09:00	Systems biology defines biomarkers of neonatal hepatitis B vaccine immunization <a href="#">Ofar Levy, Harvard Medical School, USA</a>
09:00	09:30	Effect of BCG Danish and oral polio vaccine on neonatal mortality in newborn babies weighing less than 2000 g in India: multicentre open label randomised controlled trial (BLOW2) <a href="#">Bethou Adhisivam, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India</a>
09:30	09:45	Bacillus Calmette–Guérin (BCG) vaccination and mortality in Quebec, Canada: Influence of timing and number of doses <a href="#">Jérémy Lelièvre, Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique (INRS), Canada</a>
09:45	10:00	Maternal influenza vaccine reduces the risk of RSV and related respiratory hospitalisations in early infancy: an epidemiological study <a href="#">Charlie Holland, The Kids Research Institute Australia, Australia</a>
10:00	10:30	Discussion
10:30	10:50	Coffee Break
10:40		Briefing for Keynote, chair, moderator & committee - Auditorium
<b>10:50</b>	<b>12:30</b>	<b>Keynote lecture 3</b>
10:50	11:20	Of paradigms and pragmatism <a href="#">Naor Bar-Zeev, Johns Hopkins Bloomberg School of Public Health, USA</a>
<b>11:20</b>	<b>12:20</b>	<b>Panel: From genomics to policy - how does public health integrate findings from genomics?</b>
		<a href="#">Naor Bar-Zeev, Johns Hopkins Bloomberg School of Public Health, USA</a> <a href="#">Julier Nabyongo, North-West University, South Africa</a> <a href="#">Hanna Nohynek, Finnish Institute for Health and Welfare (THL), Finland</a> <a href="#">Katie Flanagan, RMIT University, University of Tasmania &amp; Australian Technical Advisory Group on Immunization, Australia</a>
<b>12:20</b>	<b>12:30</b>	<b>Closing Remarks</b>
		<b>Scientific Programme Committee:</b> <a href="#">Christine Stabell Benn, University of Southern Denmark, Denmark</a> <a href="#">Eleanor Fish, University of Toronto, Canada</a> <a href="#">Katie Flanagan, RMIT University, University of Tasmania &amp; Australian Technical Advisory Group on Immunization, Australia</a> <a href="#">Jim Buttery, University of Melbourne, Australia</a> <a href="#">Sabra Klein, Johns Hopkins, USA</a>
12:30		Lunch and departures
13:40		Coach departures for Stansted and Heathrow airports
13:50		Coach departures for Cambridge train station and city centre